SB 226 – LouisianaStatus: Inactive / Dead
Year Introduced: 2018
MAXIMUM ALLOWABLE DRUG PRICING IN THE MEDICAID PHARMACY PROGRAM: Requires a pharmaceutical drug manufacturer to remit a combination of federal and state supplemental rebates in an amount that will make the net cost of the drug no more than is available to other enumerated entities in order for the drug to be included on the Medicaid preferred drug list.
Return to Database Search
© 2018- The SLIHCQ Database. Initial funding for this project was provided by the Robert Wood Johnson Foundation. The views expressed here do not necessarily reflect the views of the Foundation.